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Background/Aims: There has been a lack of research com-
paring balloon dilatation and self-expandable metal stent 
(SEMS) placement to determine which is better for long-term 
clinical outcomes in patients with benign colorectal stric-
tures. We aimed to compare the clinical efficacy and com-
plication rates of balloon dilatation and SEMS placement for 
benign colorectal strictures from a variety of causes. Meth-
ods: Between January 1999 and January 2012, a total of 43 
consecutive patients who underwent endoscopic treatment 
for benign colorectal stricture (balloon only in 29 patients, 
SEMS only in seven patients, and both procedures in seven 
patients) were retrospectively reviewed. Results: Thirty-six 
patients underwent endoscopic balloon dilatation, represent-
ing 65 individual sessions, and 14 patients received a total 
of 17 SEMS placements. The initial clinical success rates 
were similar in both groups (balloon vs SEMS, 89.1% vs 
87.5%). Although the reobstruction rates were similar in both 
groups (balloon vs SEMS, 54.4% vs. 57.1%), the duration 
of patency was significantly longer in the balloon dilatation 
group compared with the SEMS group (65.5±13.3 months 
vs. 2.0±0.6 months, p=0.031). Conclusions: Endoscopic 
balloon dilatation is safe and effective as an initial treatment 
for benign colorectal stricture and as an alternative treat-
ment for recurrent strictures. (Gut Liver 2015;9:73-79)
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INTRODUCTION
Acute colorectal obstruction is a surgical emergency and is 
commonly caused by colorectal malignancies.1-4 However, be-
nign conditions, such as scarring from prior operations, radia-
tion, inflammatory bowel disease, diverticulitis, and ischemia, 
can also lead to colorectal obstruction.3-13 The most common 
cause of benign colorectal stricture is postoperative anastomotic 
stricture, which occurs commonly in the extraperitoneal distal 
rectum.3,8-13 Traditionally, benign strictures have been treated 
with surgical intervention, including resection and reanastomo-
sis.8
Since the first balloon dilatation for a benign rectal stricture 
was performed in 1984,14 endoscopic balloon dilatation has been 
regarded as a first line therapy for benign colorectal stricture, 
especially in case of postoperative stricture or inflammatory 
bowel disease.8-12,15 One previous study reported that 91.7% of 
patients had successful dilatation using the through-the-scope 
(TTS) method in 24 patients with anastomotic strictures after 
anterior rectal resection.8 No procedure-related complications 
were reported. In the setting of Crohn’s disease, a previous study 
showed that immediate success of a first dilatation was 97% in 
237 dilatations of 138 patients.16 During the follow-up of 5.8 
years, 76% of patients were able to avoid surgical treatment. 
Therefore, it is widely accepted that balloon dilatation is a safe 
and an effective method for postoperative colorectal stricture or 
inflammatory bowel disease.
Although self-expandable metal stent (SEMS) placement has 
been accepted as an alternative therapy for malignant colorectal 
obstruction,17-20 there is little evidence for the efficacy of this 
therapy in the treatment of benign colorectal strictures.21 Previ-
ous work showed that the clinical efficacy of SEMS was as high 
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as 95% in 23 patients with left-sided benign colorectal stric-
tures. However, the major complication rate was 38%, including 
8.7% of patients who had perforations.5 Until now, there has 
been a lack of evidence comparing these two endoscopic treat-
ment options to determine which is better for long-term clini-
cal outcomes in patients with benign colorectal strictures. We, 
therefore, aimed to compare the clinical efficacy and complica-
tion rates of balloon dilatation and SEMS placement for benign 
colorectal strictures from a variety of causes.
MATERIALS AND METHODS
1. Patients
Between January 1999 and January 2012, a total of 43 
consecutive patients who underwent endoscopic treatment for 
benign colorectal stricture at Severance Hospital, Yonsei Uni-
versity College of Medicine, Seoul, Korea were included in the 
present study. Among these 43 patients, 29 (67.4%) underwent 
balloon dilatation only, seven patients (16.3%) underwent SEMS 
only, and seven patients (16.3%) underwent both treatments. 
The therapeutic modality was selected by the discretion of the 
endoscopists. In total, 36 patients received a total of 65 sessions 
of endoscopic balloon dilatation and 14 patients received a total 
of 17 SEMS placements.
2. Endoscopic treatment
Endoscopic treatment with balloon dilatation or SEMS place-
ment was performed using the TTS method under fluoroscopy 
by expert endoscopists. A wide working channel endoscope 
(GIF-Q260; Olympus Optical Co., Ltd., Tokyo, Japan) was used 
for all exploration. Water soluble contrast material (gastrogra-
fin) was injected through the catheter to visualize and measure 
the length of the stricture. Then, a 7F catheter was passed en-
doscopically with the aid of a guidewire (Hydra-Jagwire 0.035 
in×450 cm; Boston Scientific, Natick, MA, USA) and inserted 
through the stricture. In cases of balloon dilatation, the TTS 
hydrostatic balloon was inserted through the stricture with aid 
of fluoroscopy and was expanded for a period of 30 seconds, 
one to two times during a session. A 15- to 20-mm balloon was 
used, depending on the stricture diameter, and was filled with 
water to obtain adequate pressure as assessed by visualization 
and pressure monitoring. In cases of SEMS placement, a Comvi® 
covered stent (Taewoong Medical Co., Ltd., Gimpo, Korea), 20 
mm in diameter and either 60, 80, 100, or 120 mm in length, a 
Niti-S® uncovered D-type stent (Taewoong Medical Co., Ltd.), 
24 mm in diameter and 60, 80, 100, or 120 mm in length, or a 
Hanarostent® covered stent (M.I.Tech Co., Ltd., Seoul, Korea), 
22 mm in diameter and 80 mm in length was selected based 
on length of stricture and used for the procedure. The length of 
the stent was chosen to allow for at least an additional 2 cm on 
each side of the obstruction to obtain adequate margins. After 
the deployment of the stent, its position was assessed by the 
endoscopists under fluoroscopic visualization. A plain X-ray 
was obtained to confirm the proper position and expansion of 
SEMS.
3. Definitions
Technical success was defined as a successful balloon dilata-
tion or stent deployment across the stricture. Clinical success 
was defined as colonic decompression or relief of obstructive 
symptoms within 48 hours after a technically successful endo-
scopic treatment. Reobstruction was defined as a recurrence of 
obstructive symptoms during follow-up after prior achievement 
of clinical success. In addition, we defined procedural failure 
as events which made a need to perform additional endoscopic 
treatment or surgery. Technical failure, clinical failure, and 
reobstruction were included in procedural failure. In addition, 
duration of patency was defined as the time from the initial 
endoscopic treatment to the first procedural failure. Endoscopic 
treatment failure was defined as the condition of the patients 
who were not able to continue to undergo further endoscopic 
treatment despite indications for further therapy, or underwent 
surgical treatment including ileostomy or colostomy. The medi-
cal records of all patients were retrospectively reviewed, includ-
ing patient demographics, cause, location and duration of the 
colorectal obstruction, clinical efficacy of therapy, occurrence of 
complications, and mortality. The Institutional Review Board of 
Severance Hospital approved this study.
4. Statistical analysis
Categorical variables including cause and location of stric-
ture, technical and clinical success, reobstruction, and proce-
dural failure were analyzed using a chi-square or Fisher exact 
test. Continuous variables, such as age, were analyzed with the 
Mann-Whitney U test. Variables with p-values of 0.2 or less in 
the univariate analysis were included in the multivariate logis-
tic regression model. Age and sex were also adjusted for in the 
logistic regression analysis. For analysis of duration of patency 
between balloon dilatation and SEMS placement group was 
compared by using a Kaplan-Meier plot and the log-rank test. 
p-values of less than 0.05 were considered significant. Statistical 
analysis was performed using SPSS version 18.0 for Windows 
(SPSS Inc., Chicago, IL, USA).
RESULTS
1. Patient characteristics
The baseline characteristics of study participants are shown 
in Table 1. The median age was 58 years (range, 26 to 77 years) 
in the balloon dilatation group and 62 years (range, 31 to 84 
years) in the SEMS group (p=0.626). Men represented 47.2% 
of the balloon dilatation group and 35.7% of the SEMS group 
(p=0.462). The patients with the Eastern Cooperative Oncology 
Group (ECOG) performance status 0 or 1 were more common in 
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the balloon dilatation group than in the SEMS group (83.3% vs 
42.9%, p=0.011). Anastomotic stricture was the main cause of 
benign colorectal strictures in both groups (balloon vs SEMS, 
66.7% vs 71.4%; p=0.705), followed by radiation, ischemia, and 
inflammatory disease. Most strictures were located at the rectum 
in both groups.
2. Short-term clinical efficacies and complications
The overall technical and clinical success rates were similar in 
both groups (Table 2). In the balloon dilatation group, 98.5% of 
cases resulted in technical success and in 89.1% of cases clini-
cal success was also achieved. In the SEMS group, 94.1% and 
87.5% achieved technical and clinical success, respectively. In 
the SEMS group, five uncovered stents and 11 covered stents 
were used. The guidewire could not be inserted in one patient. 
Reobstruction occurred in 54.4% of patients in the balloon 
dilatation group and in 57.1% of the SEMS group (p>0.999). In 
the balloon dilatation group, perforation and fistula occurred 
during two (3.1%) and one (1.5%) of the sessions, respectively 
(Table 2). One perforation occurred during balloon dilatation for 
postoperative stricture at the transverse colon, and it was treated 
with surgery. The other perforation developed in a patient with 
ischemia-induced rectal stricture. The patient’s complication 
was completely resolved by conservative care including fasting, 
hydration, and antibiotics. In the SEMS group, stent migra-
tion occurred in 31.3% of cases (n=5; one uncovered and four 
covered stents). There were no cases of mortality related to the 
procedure. 
3. Predictive factors for clinical success and risk factors for 
procedural failure
In the balloon dilatation group, univariate analysis demon-
strated that good functional performance (ECOG 0 or 1) was a 
significant predictive factor for clinical success (p=0.018, data 
not shown). Age, sex, cause of colorectal stricture, location of 
stricture, length of stricture, and previous endoscopic treatment 
were not significantly related to clinical success. In the SEMS 
group, no significant predictive factors were identified.
In the balloon dilatation group, the univariate analysis 
showed that having a radiation-related stricture was a sig-
Table 1. Baseline Characteristics of Patients and Lesions Treated with 









No. of session 65 17
Age, yr 58 (26–77) 62 (31–84) 0.626
Sex 0.462
    Male 17 (47.2) 5 (35.7)
    Female 19 (52.8) 9 (64.3)
ECOG-PS 0.011
    0, 1 30 (83.3) 6 (42.9)
    2, 3, 4 6 (16.7) 8 (57.1)
Underlying disease
    Hypertension 6 (16.7) 6 (42.9) 0.071
    Diabetes 4 (11.1) 2 (14.3) >0.999
    Chronic kidney disease 1 (2.8) 0 NA
    Inflammatory disease 4 (11.1) 0 NA
    Previous malignancy 31 (86.1) 13 (92.9) 0.663
Cause of colorectal stricture 0.705
    Anastomotic stricture 24 (66.7) 10 (71.4)
    Radiation 5 (13.9) 3 (21.4)
    Inflammatory disease* 4 (11.1) 0
    Ischemia 3 (8.3) 1 (7.1)
Location of stricture 0.875
    Rectum 20 (55.6) 8 (57.1)
    Sigmoid colon 10 (27.8) 3 (21.4)
    Descending colon 1 (2.8) 0
    Transverse colon 5 (13.9) 3 (21.4)
Length of stricture, cm 0.252
    <4 30 (83.3) 9 (64.3)
    ≥4 6 (16.7) 5 (35.7)
Data are presented as number (%) or median (range).
SEMS, self-expandable metal stent; ECOG-PS, Eastern Cooperative 
Oncology Group performance status; NA, not applicable.
*Inflammatory disease includes inflammatory bowel disease, intesti-
nal tuberculosis, and diverticulitis.
Table 2. Short-Term Clinical Efficacy and Complications of Balloon 








    Technical success 64 (98.5) 16 (94.1) 0.374
    Clinical success* 57 (89.1) 14 (87.5) >0.999
    Reobstruction† 31 (54.4) 8 (57.1) >0.999
    Procedural failure 39 (60.0) 11 (64.7) 0.723
Complication
    Perforation 2 (3.1) 0 NA
    Fistula 1 (1.5) 0 NA
    Bleeding 0 0 NA
    Migration‡ NA 5 (31.3) NA
Total 65 17
Data are presented as number (%).
SEMS, self-expandable metal stent; NA, not applicable.
*The clinical success rate was calculated as the percentage of the 
sessions resulting in technical success; †The reobstruction rate was 
calculated as the percentage of sessions resulting in clinical success; 
‡The migration rate was calculated as the percentage of the 16 ses-
sions resulting in technical success.
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nificant risk factor for procedural failure (p=0.014) (Table 3). 
Multivariate analysis showed that having a radiation-related 
stricture (odds ratio [OR], 20.122; 95% confidence interval [CI], 
1.862 to 217.469) and having a stricture over 4 cm in length 
(OR, 13.581; 95% CI, 1.040 to 177.394) were independent risk 
factors for procedural failure, even when controlling for other 
important factors. Age, sex, ECOG performance status, location 
of stricture, and previous endoscopic treatment were not sig-
nificantly related to procedural failure. In the SEMS group, no 
significant risk factor was identified.
4. Clinical course of patients
Clinical course of patients enrolled in this study was present-
ed in Fig. 1. In 35 patients who had undergone balloon dilata-
tion as an initial treatment, 18 (51.4%) underwent additional 
endoscopic treatments. In comparison, in eight patients who had 
received SEMS placement as an initial treatment, three (37.5%) 
were treated with additional endoscopic treatments. Finally, en-
doscopic treatment failure was observed in 3 of 29 (10.3%), 2 of 
7 (28.6%), and 6 of 7 (85.7%) in the patients underwent balloon 
dilatation only, SEMS placement only, and both treatments, 
respectively. Of the total 11 patients with endoscopic treatment 
failure, seven underwent either ileostomy or colostomy for ob-
struction following endoscopic treatment failure. Another three 
patients underwent segmental resection or Hartmann operation. 
The remaining one patient refused additional treatment and was 
lost to follow-up.
5. Duration of patency
In order to assess duration of patency according to the en-
Table 3. Risk Factors for Procedural Failure Following Balloon Dilatation or Self-Expandable Metal Stent Placement*
Variable











p-valueOR 95% CI p-value
Age, yr 0.543 >0.999
    Young (<65) 32 18 (56.3) 1 - 9 6 (66.7)
    Old (≥65) 33 21 (63.6) 0.560 0.140–2.242 0.413 8 5 (62.5)
Sex >0.999 >0.999
    Male 35 21 (60.0) 1 - 6 4 (66.7)
    Female 30 18 (60.0) 0.245 0.053–1.135 0.072 11 7 (63.6)
ECOG-PS 0.158 0.304
    0, 1 49 27 (55.1) 1 - 7 6 (85.7)
    2, 3, 4 16 12 (75.0) 2.170 0.446–10.547 0.337 10 5 (50.0)
Cause of colorectal stricture 0.014 >0.999
    Anastomotic stricture 41 23 (56.1) 1 - 11 7 (63.6)
    Radiation 13 12 (92.3) 20.122 1.862–217.469 0.013 4 3 (75.0)
    Inflammatory disease† 5 1 (20.0) 0.070 0.004–1.242 0.070 0 0 
    Ischemia 6 3 (50.0) 0.428 0.047–3.918 0.453 2 1 (50.0)
Location of stricture 0.832 0.322
    Rectum 37 23 (62.2) 10 8 (80.0)
    Sigmoid colon 18 10 (55.6) 3 1 (33.3)
    Descending colon 4 3 (75.0) 0 0 
    Transverse colon 6 3 (50.0) 4 2 (50.0)
Length of stricture, cm 0.177 0.644
    <4 54 30 (55.6) 1 - 10 7 (70.0)
    ≥4 11 9 (81.8) 13.581 1.040–177.394 0.047 7 4 (57.1)
Previous endoscopic treatment 0.310 >0.999
    Presence 30 20 (66.7) 9 6 (66.7)
    Absence 35 19 (54.3) 8 5 (62.5)
Data are presented as number (%).
SEMS, self-expandable metal stent; OR, odds ratio; CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group performance status.
*Procedural failure included technical failure, clinical failure, and reobstruction, which required additional endoscopic treatment or surgery; †In-
flammatory disease includes inflammatory bowel disease, intestinal tuberculosis, and diverticulitis.
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doscopic treatment modality, we compared duration of patency 
between 29 patients who underwent balloon dilatation only 
and seven patients who underwent SEMS placement only. The 
median follow-up period was 10.2 months (range, 0 to 130.0 
months) in the balloon dilatation group and 0.3 months (range, 
0 to 2.9 months) in the SEMS group. Patency was of longer du-
ration in the balloon dilatation group than in the SEMS group 
(65.5±13.3 months vs 2.0±0.6 months, p=0.031) (Fig. 2). 
DISCUSSION
The present study demonstrates that balloon dilatation had 
favorable clinical outcomes, with an 89.1% rate of initial suc-
cess and 4.6% rate of procedure-related complications in the 
setting of benign colorectal strictures.
Benign colorectal strictures occur frequently after colorec-
tal surgery for both benign and malignant disease.3,8-13 The 
rectum is the most common site of anastomotic strictures and 
is treated according to the severity of symptoms.9,11-13 Before 
the popularization of endoscopic balloon dilatation, dilatation 
was performed using rubber bougies, Foley catheter balloons, 
esophageal dilators, and other metal dilators in patients with se-
vere strictures.22,23 In contrast with the longitudinal bougienage, 
only radially directed forces are applied with balloon dilatation. 
Therefore, the risk of viscus perforation is decreased, and the 
endoscopic approach with TTS also allows for direct visualiza-
tion of the stricture and the procedure.14 Recent studies with 
endoscopic balloon dilatation have reported that among small 
samples of patients with anastomotic strictures, there is a 91.7% 
to 100% initial success rate.8,9 These studies also demonstrate 
favorable long-term clinical efficacy, with only 5.9% to 18.2% 
of patients with successful dilatation experiencing recurrence of 
symptomatic strictures.8,9 However, available data suggest that 
the long-term patency of balloon dilatation is dependent on the 
cause of the benign stricture. Although endoscopic balloon dila-
tation showed good immediate efficacy in patients with Crohn’s 
disease, 56% of patients experienced recurrences.16 The present 
study revealed that radiation-induced stricture may also be a 
poor indication for endoscopic treatment, as 92.3% of patients 
with radiation-induced stricture experienced reobstruction. An-
other advantage of endoscopic balloon dilatation is that it can 
be performed repeatedly for patients with recurrence after initial 
success. In previous studies, all of the recurrences of anasto-
motic strictures were successfully treated with repeat balloon 
dilatation.8,11 Among patients with Crohn’s disease, 46% of pa-
tients received a new dilatation, and ultimately, 76% of patients 
were able to avoid surgical treatment.16 In the present study, an 
average of 1.8 sessions of balloon dilatation was performed per 
patient, and ultimately, 75% of patients with various causes of 
benign colorectal strictures were able to avoid surgical treat-
Fig. 1. Clinical course of patients enrolled in this study.
SEMS, self-expandable metal stent.
35 Balloon dilatation
43 Benign colorectal stricture
8 SEMS placement
2 Patent 1 Surgery recommendation
(follow-up loss)
16 Patent 3 Patent1 Surgery 2 Surgery
18 Repeated
endoscopic treatment
12 Ballon dilatation only







Fig. 2. Kaplan-Meier plots of the patency of initial endoscopic treat-
ments in 29 patients who underwent balloon dilatation only and 
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ment.
Endoscopic balloon dilatation has been shown to be a safe 
procedure. However, perforation is the most serious complica-
tion related to balloon dilatation. One previous study reported 
an 8.7% rate of all complications requiring hospitalization, 
including a 4.3% rate of perforation in patients with Crohn’s 
disease.13 The present study also confirmed the general safety of 
the balloon dilatation procedure. Even so, perforation occurred 
at a rate of 3.1% per session and 5.6% per patient, and one pa-
tient required emergent surgical treatment. Choice of adequate 
balloon size according to the diameter of the stricture and a 
slow increase in balloon pressure, especially after visualization 
of the balloon in contact with the viscus wall might reduce 
the risk of perforation. Notably, after successful dilatation, the 
forceful advancement of the scope across the stricture can cause 
perforation and should be avoided when possible. 
Unfortunately, the present study showed poor efficacy of 
SEMS in patients with benign colorectal strictures. Considering 
recent advances and clinical outcomes of SEMS in malignant 
disease, this is disappointing.13,24 Although the initial success 
rate of SEMS was high, the present study showed that patency 
was significantly shorter than that following balloon dilata-
tion. Another limitation of SEMS for benign stricture is the high 
complication rate, up to 71.4% of patients in studies reported in 
the literature.25 Stent migration is one of the major complica-
tions, and 31.3% of patients experienced it in the present study. 
One recent pilot study of patients with Crohn disease reported a 
rate of stent migration as high as 60%.26 Although stent-related 
perforation did not occur in the present study, it is the most se-
rious complication. Previous studies have reported rates 28.6% 
for perforation and 4.8% for mortality in patients undergoing 
this procedure with benign colorectal strictures.6 Thus, at this 
point, SEMS is not a reasonable alternative therapy for benign 
colorectal strictures.
The present study was not without limitations; it suffers 
from retrospective design and a relatively small sample size. 
For these reasons, the baseline characteristics of the two study 
groups were not able to be controlled or randomized. The poor 
baseline performance status of the patients in the SEMS group 
might have contributed to the observed poor long-term clinical 
efficacy. We think that it is difficult to draw a definite conclu-
sion based on this retrospective study. This study, however, has 
a larger sample size compared to earlier studies.3-13 Therefore, 
it might be helpful to select an endoscopic treatment option in 
patients with benign colorectal strictures. Although the study 
showed duration of patency was longer in the balloon dilata-
tion group than in the SEMS group, short follow-up duration 
and relatively high proportion of censored data (62.5%) in the 
SEMS group were additional limitations. In order to guarantee 
superiority of balloon dilatation for patency, therefore, long-
term follow-up data should be needed. However, we think that 
balloon dilatation may be acceptable as an initial treatment op-
tion for benign colorectal stricture, because it is easy to undergo 
additional endoscopic treatment when the balloon dilatation 
was performed firstly.
In conclusion, endoscopic balloon dilatation is a safe and an 
effective treatment for benign colorectal strictures. We recom-
mend endoscopic balloon dilatation as an initial therapeutic 
option for benign colorectal strictures and as an alternative 
treatment after recurrence. Further study is mandatory to deter-
mine whether there is a role for SEMS in patients with benign 
colorectal strictures.
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